WHHO RECOMMENDS LENACAPAVIR AS TWICE YEARLY INJECTION TO HELP PREVENT HIV

Lenacapavir is a Medication Originally Designed to Treat Hiv Infection. It is Currently Sold Under The Brand Names Sunlenca for Hiv Treatment, and yeztugo for HIV prevention.

According to Carolyn Chu, MD, MSC, FAAFP, AAHIVS, CHIEF Medical Officer of the American Academy of Hiv Medicine, Lenacapavir is a novel antiviral medication – Belonging to the “HIV Capsid Inhibitor” Class – WHICH WAS INITIALLY DEVELOPED FOR USE AS PART OF A COMBINATION TREAT. People with HIV.

“The Initial Product (Brand Name Sunlenca) was approved for treatment in late 2022 Based on the Capella Study that Examined ITS Safety and EFFICACY AMONG STUDY participants With HIV WHO WERE HERRE HEAVIL TREATMENT-EXPERRIED AND HAD MULTIDRUR-RESISTANT INFECTION,” Medical News Today.

“Because of its unique Molecular Properties, Scientists were very intersted in determining WHOTHER Lenacapavir Could Also Be Developed for Use As An Hiv Prevention Intervention,“ She Added.

“(Lenacapavir) Disrupts Multiple Stages of the HIV Life Cycle, Which Makes It An Attractive Drug To Study Further-It is also Vary Power Commonly used over the last decade. “
– Carolyn Chu, MD

Chu Said That When Lenacapavir Was Studied as A Long-Action Pre-Exposure Prophylaxis (PREP) HIV Preventive Option in the Purpose Clinical Trials, Investigators Found an almost 100% Reduction in New HIV Infections among participants Who Receive It As a Twice-Iarly Injection.

“BeSe Findings Led To ITS Recent Approval Under A New Indication, IE, Used A Prevention Medication, Brand Name Yeztugo,” She Added.

Through us new Guidelines, The Who Recommends The Use of Injection Lenacapavir Twice A Year As an Addionional Prep option to Help Prevent HIV.

Example of Currently used prep options include the oral medications truvada (Emtricitabine/Tenofovir Disoproxil fumarate) and Decovy (Emtricitabine/Tenofovir alafenamide), and the injection Drug Aprentude (Cabotegravir).

The Who Also recommended the Dapivirine Vaginal Ring (DVR) In 2021 as an additional prep choice for cisgender women.

The Guidelines Are Based on Safety and Efficacy Findings for Lenacapavir from Various Studies and Clinical Trials, Most Notabry Purpose 1 and Purpose 2.

Phase 3 of the purpose 1 trial in Cisgender Women is no case of Hiv Infection Among Study Participants Given Lenacapavir.

Further, The Purpose 2 Trial Found 99.9% of Cisgender Men and Gender-Diverse People Did Not Become Infected with HIV AFTER REVIVING THE DRUG.

In Addition to The Lenacapavir Recommendation, The Who Also Recommends A Public Health Approach To Hiv Testing Through the Use of Hiv Rapid Tests.

ACCORDING TO THE WHO’S NEW GUIDELINES, INJECTABLE OFFERING LENACAPAVIR TWICE A YEAR MAY HELP OVERCOM POTENTIAL BARRIERS TO CURRENT PREP OPTIONS, SUCH AS UNWILLINGNESS TO TAKE TO REGULAR ORAL PILL AND A WISH FOR LOWER AMOUTS OF CLINIC VISITS.

“Lenacapavir Represents a Major Scientific Advance-It’s the First Long-Action Injection HIV Prevention Strategy That required Dosing Just Twice A Year,” Chu Toled MNT.

“For Sub individuals, Specially Those Who Have Difficulty Adhering to Daily or Even Bimontly Prevention Strategies Like Oral Prep or Cabotegravir, This Would Be Specially Welcome,” She Notted.

Edward Liu, MD, MPH, FACP, FIDSA, CHIEF OF INFECTIUS DESIGNS AT HACKENSACK MERIDIAN JERSEY SHORE UNIVERSITY MEDICAL CENTER IN NEW Jersey, Explained To MNT That:

“Across The World HIV Remains A Serious Disease and Preventing New Infection is critical. Lenacapavir is an in -art -convertible antiviral that Lasts 6 months, Protecting People for Long periods of time.

“People Don’t Like Storing Oral HIV Antivirals at Home, WHERE there is stigma attical to thhos medications, and people forget to take a medications or use condoms,” liu continue. “Large-Scale Treatment of People With Lenacapavir Will Be The Most Efficient Way Yet To Prevent Hiv Infection Until An Effective Vaccine Is Produced.”

HIV and AIDS Continue to Be a Global Problem. According to Unaids, Although The Number of New Global Hiv Infections have decreased by About 39% Since 2010, There are Still Areas Around the World Where Numbers are Increaseing, Making The Need for Hiv Prevention Critical.

“Prevention of HIV is a lot of Lessive than Treating People with Hiv Infection with Expensive Antivirals for The Rest of Their Lives,” Commented Paul E. Sax, MD, Clinical Director of the Division of Infectious Diseases At The Brigham and Women’s Hospital, and Professor of Medical At Medical Medical School.

That is Another Reason Why Prevention is Important. “Treatment with antivirals is Vary Difficul to Sustain, particularly in poorer country,” Said Sax.

“The ideal situation is to have multiple options for preventing HIV Among Those at Risk-This includes not only showable prep strategies, but also other novel novel prepress apoproaches Such as an investigational eleven-monthly pill for those Who don’t Like or want injection,” I have explained. “

“Of Course, We Still Hope That the HIV Vaccine Research Will Advance To The Point of Giving Us An Effective Vaccine, But The Scientific Hurdles Have Acks CAUTIONARY Note.

FINALLY, CHU NOTED THAT:

“Right Now, a Lot of Conversations are Centen on Requireing that Everyone Who is intersted in (Lenacapavir) Will Have Access to It. Multiple Studies have confirmed that Interest in This New Option is high Collaboration with Community Members and Other Stakeholders To Ensure That All The Necessary Pieces To Initiate and Continue This New Prep option (EG, HIV Screening/Testing, Obtaining the Medication from Pharmacies, Training People On How To Administer The Doses, Relaying Medication/Appaintment Reminders, etc.) are identified soon and can be rolled out equitlock. ”